Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 12 | 2019 | 198 | 2.610 |
Why?
|
| Prostatectomy | 14 | 2016 | 472 | 2.380 |
Why?
|
| Urethra | 7 | 2020 | 105 | 2.070 |
Why?
|
| Postoperative Complications | 20 | 2017 | 2552 | 1.990 |
Why?
|
| Prostatic Hyperplasia | 11 | 2016 | 95 | 1.830 |
Why?
|
| Urinary Sphincter, Artificial | 8 | 2019 | 14 | 1.810 |
Why?
|
| Penis | 5 | 2015 | 61 | 1.570 |
Why?
|
| Reoperation | 7 | 2017 | 696 | 1.380 |
Why?
|
| Botulinum Toxins, Type A | 6 | 2017 | 53 | 1.300 |
Why?
|
| Urinary Bladder | 10 | 2020 | 257 | 1.160 |
Why?
|
| Urethral Diseases | 3 | 2015 | 14 | 1.160 |
Why?
|
| Risk Assessment | 6 | 2016 | 2434 | 1.150 |
Why?
|
| Neuromuscular Agents | 5 | 2017 | 27 | 1.130 |
Why?
|
| Patient Readmission | 4 | 2017 | 403 | 1.130 |
Why?
|
| Urologic Diseases | 6 | 2016 | 38 | 1.070 |
Why?
|
| Ureter | 4 | 2016 | 80 | 1.030 |
Why?
|
| Cystectomy | 8 | 2016 | 113 | 1.010 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2017 | 95 | 0.990 |
Why?
|
| Suburethral Slings | 5 | 2016 | 77 | 0.980 |
Why?
|
| Penile Prosthesis | 4 | 2017 | 24 | 0.960 |
Why?
|
| Penile Diseases | 2 | 2015 | 8 | 0.900 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 191 | 0.860 |
Why?
|
| Urinary Diversion | 5 | 2016 | 41 | 0.840 |
Why?
|
| Robotic Surgical Procedures | 3 | 2016 | 366 | 0.700 |
Why?
|
| Laparoscopy | 8 | 2016 | 765 | 0.700 |
Why?
|
| Urinary Retention | 4 | 2014 | 44 | 0.700 |
Why?
|
| Urologic Surgical Procedures | 9 | 2017 | 148 | 0.650 |
Why?
|
| Urinary Incontinence | 6 | 2014 | 217 | 0.640 |
Why?
|
| Urethral Stricture | 2 | 2015 | 15 | 0.620 |
Why?
|
| Abdominal Cavity | 1 | 2020 | 17 | 0.620 |
Why?
|
| Replantation | 2 | 2016 | 35 | 0.590 |
Why?
|
| Male | 53 | 2020 | 44355 | 0.570 |
Why?
|
| Humans | 77 | 2020 | 93132 | 0.550 |
Why?
|
| Incontinence Pads | 2 | 2016 | 4 | 0.530 |
Why?
|
| Pubic Bone | 1 | 2017 | 9 | 0.510 |
Why?
|
| Suture Anchors | 1 | 2017 | 7 | 0.510 |
Why?
|
| Urination | 3 | 2016 | 39 | 0.510 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 170 | 0.510 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 282 | 0.510 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 53 | 0.500 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 133 | 0.490 |
Why?
|
| Ureteral Diseases | 1 | 2016 | 11 | 0.480 |
Why?
|
| Surgical Wound | 1 | 2016 | 7 | 0.480 |
Why?
|
| Surgical Flaps | 3 | 2014 | 251 | 0.480 |
Why?
|
| Free Tissue Flaps | 1 | 2017 | 54 | 0.470 |
Why?
|
| Middle Aged | 36 | 2020 | 27535 | 0.460 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 5 | 0.440 |
Why?
|
| Hysterectomy | 1 | 2016 | 167 | 0.430 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 71 | 0.430 |
Why?
|
| Follow-Up Studies | 19 | 2016 | 3814 | 0.430 |
Why?
|
| Aged | 33 | 2020 | 20395 | 0.420 |
Why?
|
| Urinary Bladder Neck Obstruction | 5 | 2015 | 25 | 0.420 |
Why?
|
| Urinary Bladder Diseases | 4 | 2008 | 40 | 0.370 |
Why?
|
| Urinary Tract Infections | 4 | 2017 | 83 | 0.370 |
Why?
|
| Quality Improvement | 1 | 2016 | 482 | 0.360 |
Why?
|
| Urodynamics | 7 | 2020 | 126 | 0.350 |
Why?
|
| Female | 32 | 2020 | 48542 | 0.350 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2016 | 376 | 0.340 |
Why?
|
| Aged, 80 and over | 16 | 2017 | 7039 | 0.330 |
Why?
|
| Treatment Outcome | 16 | 2016 | 9070 | 0.320 |
Why?
|
| Risk Factors | 8 | 2016 | 5900 | 0.320 |
Why?
|
| Rectus Abdominis | 2 | 2008 | 41 | 0.310 |
Why?
|
| Uterine Prolapse | 2 | 2008 | 82 | 0.300 |
Why?
|
| Surgical Mesh | 2 | 2008 | 125 | 0.300 |
Why?
|
| Cystoscopy | 4 | 2015 | 36 | 0.290 |
Why?
|
| Penile Implantation | 1 | 2009 | 13 | 0.290 |
Why?
|
| Transsexualism | 1 | 2009 | 24 | 0.290 |
Why?
|
| Prostatism | 1 | 2008 | 5 | 0.280 |
Why?
|
| Botulinum Toxins | 1 | 2008 | 16 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2020 | 1004 | 0.280 |
Why?
|
| Adult | 22 | 2020 | 27849 | 0.280 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2008 | 16 | 0.270 |
Why?
|
| Vesicovaginal Fistula | 1 | 2008 | 12 | 0.270 |
Why?
|
| Urination Disorders | 1 | 2008 | 52 | 0.270 |
Why?
|
| Prostatic Neoplasms | 6 | 2000 | 1769 | 0.260 |
Why?
|
| United States | 8 | 2017 | 7581 | 0.250 |
Why?
|
| Sacrum | 2 | 2017 | 81 | 0.250 |
Why?
|
| Diagnostic Techniques, Urological | 2 | 2017 | 14 | 0.250 |
Why?
|
| Time Factors | 8 | 2016 | 5380 | 0.240 |
Why?
|
| Quality of Life | 5 | 2008 | 1776 | 0.240 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 162 | 0.240 |
Why?
|
| Iatrogenic Disease | 2 | 2016 | 69 | 0.240 |
Why?
|
| Cysts | 1 | 2007 | 99 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2016 | 4546 | 0.230 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2015 | 14 | 0.230 |
Why?
|
| Fournier Gangrene | 1 | 2005 | 2 | 0.230 |
Why?
|
| Retrospective Studies | 14 | 2020 | 10128 | 0.230 |
Why?
|
| Tissue Expansion | 1 | 2005 | 18 | 0.230 |
Why?
|
| Scrotum | 1 | 2005 | 14 | 0.230 |
Why?
|
| Morbidity | 2 | 2016 | 162 | 0.220 |
Why?
|
| Fibula | 1 | 2005 | 31 | 0.220 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2005 | 18 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 77 | 0.210 |
Why?
|
| Pancreas Transplantation | 1 | 2005 | 104 | 0.210 |
Why?
|
| Device Removal | 2 | 2017 | 166 | 0.200 |
Why?
|
| Administration, Intravesical | 3 | 2008 | 34 | 0.200 |
Why?
|
| Preoperative Care | 3 | 2000 | 404 | 0.190 |
Why?
|
| Hypospadias | 1 | 2002 | 6 | 0.190 |
Why?
|
| Amputation, Traumatic | 1 | 2002 | 9 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 3 | 2000 | 337 | 0.190 |
Why?
|
| Nephrectomy | 2 | 2015 | 278 | 0.180 |
Why?
|
| Urology | 2 | 2001 | 132 | 0.180 |
Why?
|
| Anastomosis, Surgical | 3 | 2016 | 280 | 0.180 |
Why?
|
| Fascia | 1 | 2001 | 32 | 0.170 |
Why?
|
| Incidence | 2 | 2016 | 1697 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2001 | 618 | 0.170 |
Why?
|
| Biofeedback, Psychology | 1 | 2000 | 13 | 0.160 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2000 | 10 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 83 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2000 | 94 | 0.150 |
Why?
|
| Pressure | 2 | 2019 | 165 | 0.150 |
Why?
|
| Ureteral Obstruction | 2 | 2002 | 60 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 210 | 0.150 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 82 | 0.140 |
Why?
|
| Collagen | 1 | 2000 | 301 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2020 | 167 | 0.140 |
Why?
|
| Cryosurgery | 2 | 1995 | 67 | 0.140 |
Why?
|
| Phytotherapy | 1 | 1999 | 137 | 0.140 |
Why?
|
| Urinary Catheterization | 4 | 2014 | 39 | 0.130 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1997 | 5 | 0.130 |
Why?
|
| Platinum Compounds | 1 | 1997 | 29 | 0.130 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 31 | 0.130 |
Why?
|
| Seminoma | 1 | 1997 | 15 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 2017 | 73 | 0.130 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2008 | 39 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 48 | 0.130 |
Why?
|
| Length of Stay | 3 | 2016 | 820 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2017 | 232 | 0.120 |
Why?
|
| Creatinine | 1 | 1997 | 293 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 13 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 120 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2017 | 178 | 0.120 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 207 | 0.120 |
Why?
|
| Pelvis | 1 | 2016 | 99 | 0.120 |
Why?
|
| Orchiectomy | 1 | 1996 | 63 | 0.120 |
Why?
|
| Anilides | 1 | 1996 | 45 | 0.110 |
Why?
|
| Abdomen | 1 | 2016 | 118 | 0.110 |
Why?
|
| Organ Size | 1 | 2016 | 360 | 0.110 |
Why?
|
| Operative Time | 1 | 2016 | 167 | 0.110 |
Why?
|
| Rupture | 1 | 2015 | 57 | 0.110 |
Why?
|
| Recurrence | 2 | 2016 | 1188 | 0.110 |
Why?
|
| Survival Rate | 3 | 2015 | 1945 | 0.110 |
Why?
|
| Rhabdomyolysis | 1 | 2015 | 28 | 0.110 |
Why?
|
| Steroids | 1 | 2016 | 166 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2016 | 319 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 156 | 0.110 |
Why?
|
| Age Factors | 3 | 2016 | 1898 | 0.110 |
Why?
|
| Reference Values | 1 | 2016 | 603 | 0.110 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 143 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 413 | 0.110 |
Why?
|
| Illinois | 1 | 2016 | 515 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2013 | 3044 | 0.110 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2013 | 29 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 328 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2016 | 289 | 0.100 |
Why?
|
| Urinary Fistula | 1 | 2013 | 7 | 0.100 |
Why?
|
| Ileum | 1 | 2014 | 167 | 0.100 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 871 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 290 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2015 | 480 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2002 | 30 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 647 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 833 | 0.090 |
Why?
|
| Delirium | 1 | 2012 | 79 | 0.090 |
Why?
|
| Sepsis | 1 | 2016 | 382 | 0.090 |
Why?
|
| Urinary Tract | 2 | 2005 | 33 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2705 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 448 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 810 | 0.080 |
Why?
|
| Kidney | 1 | 1995 | 1093 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1995 | 1447 | 0.070 |
Why?
|
| Hypertension | 1 | 1994 | 748 | 0.070 |
Why?
|
| Stents | 2 | 2002 | 406 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2012 | 913 | 0.070 |
Why?
|
| Ureteroscopy | 2 | 2000 | 34 | 0.070 |
Why?
|
| Substance P | 1 | 2008 | 60 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 2009 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2007 | 5 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 23 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2016 | 1074 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2008 | 293 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2008 | 1236 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2007 | 154 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2007 | 228 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2003 | 1910 | 0.060 |
Why?
|
| Valsalva Maneuver | 1 | 2006 | 7 | 0.060 |
Why?
|
| Prostate | 2 | 2003 | 416 | 0.060 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2005 | 4 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2301 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 483 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 1997 | 233 | 0.060 |
Why?
|
| Duodenum | 1 | 2005 | 111 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2005 | 234 | 0.050 |
Why?
|
| Internet | 3 | 2001 | 345 | 0.050 |
Why?
|
| Lithotripsy | 2 | 2000 | 42 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 158 | 0.050 |
Why?
|
| Rats | 3 | 2008 | 4028 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2003 | 3 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2000 | 354 | 0.050 |
Why?
|
| Urinary Bladder Calculi | 1 | 2002 | 2 | 0.050 |
Why?
|
| Finasteride | 1 | 2002 | 8 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 411 | 0.050 |
Why?
|
| International Cooperation | 1 | 2003 | 132 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 76 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1925 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2000 | 2787 | 0.040 |
Why?
|
| Elasticity | 1 | 2001 | 98 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 984 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2001 | 86 | 0.040 |
Why?
|
| Observer Variation | 1 | 2003 | 570 | 0.040 |
Why?
|
| Cadaver | 1 | 2001 | 195 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2008 | 808 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2003 | 212 | 0.040 |
Why?
|
| Postal Service | 1 | 2001 | 23 | 0.040 |
Why?
|
| Professional Practice | 1 | 2001 | 43 | 0.040 |
Why?
|
| Ureteral Calculi | 1 | 2000 | 9 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 359 | 0.040 |
Why?
|
| Cefazolin | 1 | 2000 | 8 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2000 | 88 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 23 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 226 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 25 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2001 | 278 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2001 | 331 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 245 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 85 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 188 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 89 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2000 | 343 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 3890 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 1997 | 22 | 0.030 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 8 | 0.030 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 29 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1519 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 247 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 1909 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 1996 | 13 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 655 | 0.030 |
Why?
|
| Contracture | 1 | 2015 | 18 | 0.030 |
Why?
|
| Nitriles | 1 | 1996 | 154 | 0.030 |
Why?
|
| Chicago | 1 | 1999 | 1452 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 67 | 0.030 |
Why?
|
| Microsurgery | 1 | 2014 | 100 | 0.020 |
Why?
|
| Logistic Models | 1 | 1997 | 1240 | 0.020 |
Why?
|
| Intestines | 1 | 2016 | 433 | 0.020 |
Why?
|
| Endoscopy | 1 | 2016 | 366 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 26 | 0.020 |
Why?
|
| Animals | 4 | 2008 | 27973 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 217 | 0.020 |
Why?
|
| Groin | 1 | 2012 | 11 | 0.020 |
Why?
|
| Biopsy | 1 | 1994 | 1172 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 709 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 874 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 986 | 0.020 |
Why?
|
| Urothelium | 1 | 2008 | 67 | 0.020 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2005 | 1 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 1719 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 944 | 0.010 |
Why?
|
| Contraindications | 1 | 2000 | 65 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2000 | 45 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 573 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 753 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 212 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 838 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 370 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 941 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 90 | 0.010 |
Why?
|
| Robotics | 1 | 2000 | 267 | 0.010 |
Why?
|
| Child | 2 | 2000 | 7273 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 494 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1997 | 119 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 129 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1727 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 291 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1998 | 1518 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1996 | 505 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 3156 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1171 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2000 | 3781 | 0.010 |
Why?
|
| Hospitalization | 1 | 1997 | 924 | 0.010 |
Why?
|
| Adolescent | 1 | 1997 | 9550 | 0.000 |
Why?
|